Evidence from
Real Clinical Practice
Our use of Arthrosamid® is informed by an independent, clinician-led clinical study, carried out as part of routine specialist knee care.
This study was not sponsored, funded, or commissioned by the manufacturer. It reflects real patient outcomes, rather than promotional or product-led data.
Arthrosamid® (a registered trademark of Contura A/S.).
Study Overview
This comprehensive evaluation provides a window into the long-term efficacy of PAAG treatments within a standard clinical setting.
Patients were reviewed over time to understand both the durability of symptom improvement and longer-term progression, including whether knee replacement was later required.
269 Patients
Total participants enrolled
314 Knees
Treated with specialist care
Bilateral Treatment: Some patients received injections in both knees where clinically appropriate.
What We Followed
Patients were assessed at baseline and during follow-up using established, patient-reported outcome measures:
- Pain (Visual Analogue Score – VAS)
- Function (Oxford Knee Score – OKS)
- Knee performance (Lysholm Score)
We also recorded:
- Age and common medical conditions (such as diabetes)
- Arthritis severity
- Whether one or both knees were injected
- Complications and tolerance
- Progression to total knee replacement over time
Meaningful improvement was defined using clinically important change thresholds, focusing on outcomes that patients actually feel in daily life.
What We Learned
"From this independent clinical study, we observed that Arthrosamid® can provide sustained improvement in pain and function for up to two years in appropriately selected patients."
Patients were more likely to benefit when they:
- Were older adults
- Had mild to moderate knee osteoarthritis
- Did not have diabetes
- Received bilateral knee injections
- Had realistic expectations focused on improvement rather than cure
Patients with more advanced arthritis were more likely to progress to knee replacement, even if short-term symptom relief occurred.
How This Study Shapes
Patient Care
This study directly informs how we use Arthrosamid® in clinic:
Not a Routine Injection
It is not offered as a standard option for every patient, ensuring targeted treatment.
Structured Assessment
Suitability is assessed carefully using a structured PAAG-8+ questionnaire.
Open Discussion
Benefits, limitations, and alternatives are discussed openly with every patient.
Joint-Preservation Strategy
Used as part of a long-term strategy, not a replacement for necessary surgery.
Why This Matters for You
Because our clinical study is independent and clinician-led,
we are able to give:
Balanced
advice
Honest
expectations
Clear guidance on whether
Arthrosamid® is likely to help you
Good outcomes come from good decisions — not just injections.
Book an Arthrosamid® Assessment – London
Long-lasting relief starts with the right decision — not just an injection.
Learn More about Arthrosamid
Deep dive into our clinical resources and patient guides.
Clinical Evidence
Evidence from Real Clinical Practice
Infection Safety
Infection Is a Serious Consideration With PAAG
Safety & Context
Arthrosamid Safety, Complications & Important Context
Full FAQ
Arthrosamid® (PAAG) Injection – Full Patient FAQ
Funding & Insurance
Funding, Insurance & NHS Coverage – Important Information
Patient Assessment
PAAG-8+ Questionnaire
Arthrosamid® (PAAG) Injection
Comprehensive Overview
Arthrosamid® is a registered trademark of Contura A/S. London Cartilage Clinic is not affiliated with or endorsed by Contura A/S.